Search | Clinical Trials Finder

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 2
States / cities: Los Angeles, California • New Hyde Park, New York

Conditions: Androgenetic Alopecia
Interventions: SM04554, Vehicle; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Encinitas, California • San Diego, California • New Haven, Connecticut + 20 more

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 2
States / cities: Paramus, New Jersey • Norfolk, Virginia

Conditions: Female Pattern Baldness
Interventions: 1550nm non-ablative fractional laser, 1927 thulium fractional laser; Device
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Male Pattern Hair Loss
Interventions: HST 001, Phosphate Buffered Saline; Biological · Other
Lead sponsor: Histogen; Industry
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions: VDPHL01, Placebo; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encino, California + 37 more

Conditions: Androgenetic Alopecia
Interventions: TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System; Device
Lead sponsor: Apira Science, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Hoboken, New Jersey • New York, New York • Rochester, New York + 1 more

Conditions: Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
Interventions: HairMax LaserComb 2009, 7 Beam, HairMax LaserComb; Device
Lead sponsor: Lexington International, LLC; Industry
Eligibility: 25 Years to 60 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Palm Beach, Florida • Austin, Texas

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 4
States / cities: Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 3
States / cities: Los Angeles, California • Las Vegas, Nevada • New Hyde Park, New York

Conditions: Androgenetic Alopecia
Interventions: Bimatoprost 1% Formulation A, Bimatoprost 1% Formulation B; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Androgenetic Alopecia
Interventions: ATI-50002; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Denver, Colorado • Portland, Oregon • Austin, Texas

Conditions: Alopecia, Androgenetic
Interventions: TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution; Drug
Lead sponsor: Technoderma Medicines Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 13
States / cities: North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more

Conditions: Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions: ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment); Dietary Supplement · Other
Lead sponsor: Arbor Life Labs; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alopecia, Androgenetic
Interventions: Puregraft System, Celution System, Kerastem Therapy, Liposuction; Device · Procedure
Lead sponsor: Kerastem Technologies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Los Angeles, California • Miami, Florida • Highland Park, New Jersey + 1 more

Conditions: Androgenetic Alopecia
Interventions: 5% minoxidil topical foam; Drug
Lead sponsor: Applied Biology, Inc.; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Tucson, Arizona • Nashville, Tennessee

Conditions: Androgenetic Alopecia
Interventions: 5% Minoxidil Topical Foam, Vehicle Topical Foam; Drug
Lead sponsor: Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more

Conditions: Alopecia, Male Pattern Hair Loss
Interventions: KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg, Matching placebo to KX-826; Drug
Lead sponsor: Suzhou Kintor Pharmaceutical Inc,; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 10
States / cities: Fountain Valley, California • Hialeah, Florida • Hialeah Gardens, Florida + 7 more

Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions: VDPHL01; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: San Diego, California • New Albany, Indiana • Hackensack, New Jersey + 1 more

Conditions: Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
Interventions: HairMax LaserComb, Control device; Device
Lead sponsor: Lexington International, LLC; Industry
Eligibility: 25 Years to 60 Years · Male only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: West Palm Beach, Florida • Hackensack, New Jersey • High Point, North Carolina

Conditions: Androgenic Alopecia
Interventions: Venus Glow; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)

1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

Safety and Efficacy of VDPHL01 in Males With AGA

Treatment of Androgenetic Alopecia in Males and Females

Treatment of Androgenetic Alopecia in Males

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss

STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia

Minoxidil Response Testing in Males With Androgenetic Alopecia

Clinical Trial in Females for Female Pattern Hair Loss

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Safety and Efficacy of VDPHL01 in Males and Females With AGA

Treatment of Androgenic Alopecia in Males

Hydraderm for Androgenic Alopecia